Exchange Traded Concepts LLC Buys 588 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Exchange Traded Concepts LLC increased its holdings in Regeneron Pharmaceuticals by 17.5%, owning a total of 3,940 shares valued at approximately $2.068 million as of Q2.
• Regeneron reported an earnings per share (EPS) of $12.89 for the last quarter, significantly surpassing the consensus estimate of $8.43, with a revenue of $3.68 billion.
• The company also declared a quarterly dividend of $0.88, providing an annualized yield of 0.6%, with a low dividend payout ratio of 8.87%.

Exchange Traded Concepts LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 17.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,940 shares of the biopharmaceutical company's stock after buying an additional 588 shares during the period. Exchange Traded Concepts LLC's holdings in Regeneron Pharmaceuticals were worth $2,068,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Polianta Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $1,365,000. Mn Services Vermogensbeheer B.V. boosted its position in Regeneron Pharmaceuticals by 1.0% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 40,000 shares of the biopharmaceutical company's stock valued at $21,000,000 after acquiring an additional 400 shares during the last quarter. Swedbank AB increased its holdings in Regeneron Pharmaceuticals by 2.0% in the second quarter. Swedbank AB now owns 228,297 shares of the biopharmaceutical company's stock worth $119,856,000 after purchasing an additional 4,509 shares in the last quarter. Sovran Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $2,750,000. Finally, Gilman Hill Asset Management LLC grew its stake in Regeneron Pharmaceuticals by 2.1% in the second quarter. Gilman Hill Asset Management LLC now owns 5,415 shares of the biopharmaceutical company's stock valued at $2,843,000 after acquiring an additional 112 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on REGN. Sanford C. Bernstein boosted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $3.69 during midday trading on Monday, hitting $595.68. The company had a trading volume of 904,767 shares, compared to its average volume of 951,771. The company has a fifty day moving average of $567.77 and a two-hundred day moving average of $574.26. The company has a market cap of $63.14 billion, a price-to-earnings ratio of 15.01, a PEG ratio of 1.98 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the firm earned $11.56 EPS. The company's revenue was up 3.6% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.